← All trials
NCT05331183
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2022
- Primary completion
- Apr 30, 2027
- Completion date
- Apr 30, 2027
- First posted
- Apr 15, 2022
- Last posted
- May 7, 2024
- Enrollment
- 297
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- VertexLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.